Background. Anal human papillomavirus (HPV) infection, most notably HPV16, the central cause of anal cancer, is increased by anal sexual intercourse and worsened by human immunodeficiency virus (HIV)-positivity.
Persistent anal human papillomavirus (HPV) infection, most notably HPV16, is the major cause of anal cancer [1] . Approximately 35 000 HPV-related anal cancers are diagnosed annually worldwide, including 17 000 among men [2] . Anal cancer incidence rates are increasing in several high-income countries [3] , a phenomenon thought to be due to changes in sexual behavior. Furthermore, in the United States at least, it has been estimated that a substantial proportion of the population-level increase among young males can be attributed to human immunodeficiency virus (HIV) infection [4] .
Anal HPV infection is known to be increased by anal sexual intercourse and worsened by HIV-related immunosuppression, so that sexual preference and HIV status are potential determinants of anal cancer risk in men. Indeed, HIV infection is known to increase the risk of anal cancer in men [5, 6] and, among HIV-positive men, anal cancer incidence is higher in men who have sex with men (MSM) than in men who have sex with women (MSW) [7, 8] . There are few data on anal cancer risk by sexual preference in HIV-negative men.
To improve our understanding of differences in risk of anal HPV infection in men, we have performed a systematic review of the literature and a meta-analysis. We aimed to assess differences in anal type-specific HPV prevalence, by HIV status and sexual preference. Given that previous meta-analyses have shown HPV16 to be uniquely carcinogenic in the anus [9] , we were particularly interested in studying anal HPV16 prevalence as a surrogate for differences in anal cancer risk between these different male subpopulations.
METHODS

Search Strategy
We performed a systematic literature review without language restrictions. MEDLINE, Embase, and the Cochrane Library were searched from 1986 up to June 2018 using the terms "papillomaviridae", "papillomavirus", or "HPV", plus "anal canal", "anus", or "anal" (as used in a previous meta-analysis [9] , for which the focus and final inclusion criteria were nonetheless different). Eligibility criteria for inclusion in the current analysis were: (1) using broad-spectrum polymerase chain reaction (PCR)-based assays to detect anal HPV DNA in men, and (2) reporting of type-specific anal HPV prevalence in men by strata of HIV status and sexual preference (see flow chart, Figure 1 ).
M A J O R A R T I C L E
When necessary, additional data were requested from study authors including, if available, stratification by anal cytopathological diagnosis.
Data Analysis
For the subset of studies with data available by anal cytopathological diagnosis, diagnoses were collapsed into 4 categories, as in a previous meta-analysis [9] : (1) normal, meaning no cytological or histological indication for anal HPV-related disease; (2) low-grade diagnosis, including atypical squamous cells of undetermined significance, low-grade squamous intraepithelial lesion (SIL) and anal intraepithelial neoplasia (AIN) grade 1; (3) high-grade diagnosis, including high-grade SIL, atypical squamous cells but cannot exclude high-grade SIL, AIN2, and AIN3; and (4) anal cancer.
Prevalence is reported as the percentage of all subjects tested by PCR as the denominator. The high-risk HPV (hrHPV) types included in this analysis are 13 carcinogenic or probably carcinogenic HPV types, that is HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 , and 69 [1] . Because not all participants were tested for the same HPV types, denominators vary by HPV type and each HPV type was assessed independently. Any and type-specific anal HPV prevalence was assessed both irrespective of anal cytopathological diagnosis and, among the subset of studies with available data, by anal cytopathological diagnosis.
Prevalence ratios (PR) and their confidence intervals (CI) were calculated between population groups, both for any HPV and specific hrHPV types, using generalized linear models [9, 10] . Nonindependence of cases within the same study was assumed by using cluster-correlated robust variance estimates [11] . In sensitivity analyses, PRs between population groups were adjusted for region.
All analyses were stratified by HIV status and sexual preference.
RESULTS
In total, 79 studies including a total of 23 700 patients were eligible for this study. Of these, 7 included HIV-negative MSW, 18 included HIV-positive MSW, 39 included HIV-negative MSM, and 73 included HIV-positive MSM (Figure 1 ; Supplementary Table 1) . Overall, 5737 patients had normal cytology, 4907 patients had a low-grade diagnosis, 1548 patients had a highgrade diagnosis, and 23 patients were diagnosed with anal cancer (Table 1 ). The proportion of included subjects with low-grade and high-grade diagnoses was approximately the same among HIV-negative (32%) and HIV-positive MSW (30%). Among MSM, the proportion of low-grade and highgrade diagnoses were higher among HIV-positive MSM (59%) compared to HIV-negative MSM (42%) (P < .001). Anal cancers were few (n = 23) and were mainly reported among HIVpositive MSM (n = 18). A majority of subjects originated from studies in Europe (36%) or North America (34%) ( Table 1) .
Irrespective of anal diagnosis, any anal HPV prevalence was highest among HIV-positive MSM (81%; 95% CI, 80%-82%) and lowest among HIV-negative MSW (12%; 95% CI, 11%-14%), whilst prevalence was comparable between HIV-positive MSW (44%; 95% CI, 41%-47%) and HIV-negative MSM (47%; 95% CI, 46%-48%) (Figure 2A ). Patterns of anal HPV16 prevalence irrespective of disease were similar to those of any anal HPV prevalence ( Figure 2B ). Anal HPV16 prevalence was highest among HIV-positive MSM (30%; 95% CI, 29%-31%) and lowest among HIV-negative MSW (3%; 95% CI, 2%-4%), with intermediate HPV16 prevalence for HIV-positive MSW and HIV-negative MSM (11%; 95% CI, 9%-13% and 14%; 95% CI, 14%-15%, respectively) ( Figure 2B ). Upon direct statistical comparison with MSW using PRs, MSM showed significantly higher prevalence of any anal HPV and anal HPV16 infection, both among HIV-negative (PR 4.8; 95% CI, 3.8-6.1 and PR 4.7; 95% CI, 2.5-8.9, respectively) and HIV-positive (PR 2.0; 95% CI, 1.5-2.7 and 2.8; 95% CI, 1.9-4.1, respectively) men (Table 2 ). On comparison with HIV-negative men, HIV-positive men showed significantly higher prevalence in any anal HPV and anal HPV16 infection, both among MSW (PR 3.6; 95% CI, 2.4-5.2 and PR 3.5; 95% CI, 2.4-5.2, respectively), and among MSM (PR 1.5; 95% CI, 1.3-1.6 and PR 1.5; 95% CI, 1.3-1.6, respectively) ( Table 2 ). In analyses irrespective of anal cytopathology, no significant differences were found between HIV-positive MSW and HIV-negative MSM (PR 1.4; 95% CI, 1.0-1.8 for any anal HPV prevalence and PR 1.3; 95% CI, 0.9-1.3 for anal HPV16 prevalence). Adjusting PRs for region yielded similar results (data not shown).
Similar patterns by HIV status and sexual preference were seen for each of the non-HPV16 hrHPV types, namely HIV-positive MSM having the highest prevalence, HIV-negative MSW the lowest, and HIV-positive MSW and HIV-negative MSM showing a comparable intermediate prevalence ( Figure 3 ). Statistical associations of type-specific hrHPV prevalence by HIV status and sexual preference were also similar to those seen for any anal HPV and anal HPV16 infections (Supplementary Table 2 ). Again, adjusting PRs for region yielded similar results (data not shown). Any anal HPV prevalence increased with increasing severity of anal diagnosis in all 4 male populations ( Figure 4A ), reaching 75%-96% among high-grade diagnoses. When stratified by anal cytopathological diagnosis, patterns of any anal HPV prevalence by sexual preference and HIV status were somewhat different from those irrespective of anal diagnosis ( Figure 4A vs Figure 2A ). Most notably, anal HPV prevalence among men with normal diagnosis was significantly lower in HIV-positive MSW (36%) than that in HIV-negative MSM (61%; PR 1.6; 95% CI, 1.1-2.3).
Anal HPV16 prevalence increased strongly with anal diagnosis severity for all 4 populations, reaching 43%-49% among men with high-grade diagnosis ( Figure 4A ). Again, patterns of anal HPV16 prevalence by sexual preference and HIV status were somewhat different when taking cytopathology into account compared to that irrespective of disease stage ( Figure 4B vs Figure 2B ). Anal HPV16 prevalence among men with normal diagnosis was lower in HIV-positive MSW (7%) than that in HIV-negative MSM (13%) but not statistically significantly so (PR 1.6; 95% CI, 0.9-3.0) ( Figure 4B ). Among men with highgrade diagnosis, no significant difference in anal HPV16 prevalence was found.
In order to address possible selection biases, Figure 5 describes any anal HPV and anal HPV16 prevalence for the 4 male populations, stratified according to whether anal cytopathology was available in the study or not. For MSW, no significant differences were found by availability of cytopathology (for any anal HPV prevalence: PR 0.8; 95% CI, 0.5-1.4 for HIV-positive MSW and PR 1.7; 95% CI, 0.6-4.6 among HIV-negative MSW; for anal HPV16 prevalence: PR 0.7; 95% CI, 0.4-1.1 for HIV-positive MSW and PR 2.5; 95% CI, 0.3-20.6 among HIV-negative MSW) ( Figure 5 ). Among MSM, however, any anal HPV prevalence was significantly higher in studies with anal cytopathlogy than those without cytopathology (PR 1.4; 95% CI, 1.2-1.7 among HIV-negative MSM and PR 1.1; 95% CI, 1.0-1.2 for HIVpositive MSM). For anal HPV16 prevalence in MSM, prevalence was also higher in studies with cytopathology than those without (PR 1.2; 95% CI, 0.9-1.5 for HIV-positive MSM and PR 1.6; 95% CI, 1.3-2.0 among HIV-negative MSM) ( Figure 5 ).
DISCUSSION
This large meta-analysis builds on previous work to provide a comprehensive picture of anal HPV infection in men, confirming that HPV16 is tightly linked to severity of anal diagnosis irrespective of HIV status and sexual preference. It also establishes both HIV infection and sexual preference as independent a Four studies provided HPV type-specific prevalence data, but not on any anal HPV infection, therefore the denominator for HIV+ MSM is smaller in the any HPV than the HPV16 analysis.
determinants of anal HPV infection, of approximately equal importance, suggesting that, based on HPV16 as a surrogate measure, HIV-negative MSM and HIV-positive MSW are at similar anal cancer risk. However, HIV infection and sexual preference combine in an additive fashion in HIV-positive MSM, who clearly stand out from other male subpopulations in terms of their anal HPV16 prevalence, and are hence priorities for male anal cancer prevention. MSM have been widely studied for anal HPV and related disease according to HIV status, so that HIV-positive MSM are known to be at a higher risk than HIV-negative MSM for anal HPV incidence [12] , HPV persistence [12] , anal high-grade squamous intraepithelial lesions (HSIL) [13] and cancer [7] .
In terms of anal HPV16 prevalence, a previous meta-analysis (including 16 studies of 4058 MSM), showed anal HPV16 prevalence to be 13% (95% CI, 10%-15%) among HIV-negative and 35% (95% CI, 33%-38%) among HIV-positive MSM [13] . These estimates remain similar in the current expansion to 73 studies of 20 971 MSM (14%; 95% CI, 13%-15% and 30%; 95% CI, 29%-31%, respectively). However, previous studies have not directly compared anal HPV16 prevalence between HIVnegative and HIV-positive MSM according to anal diagnosis, and the current meta-analysis is the first to establish higher anal HPV16 prevalence among HIV-positive than HIV-negative MSM in normal anal cytology. Increasing anal HPV16 prevalence by severity of anal cytopathological diagnosis within each of the 4 risk groups confirms the same effect previously found in men irrespective of sexual preference, and in women [9] , and is similar to that for increasing severity of cervical HPV-related disease in women [10] . There has been much less research on anal HPV infection and related disease among MSW, whether by HIV status or in comparison to MSM. In separate studies, anal HPV16 incidence rates per 1000 person-months have been reported as between 1.4 and 2.7 (according to region) for HIV-negative MSW [14] , and 4.4 for HIV-positive MSW [15] , compared to 4.7 and 9.1 for HIV-negative and HIV-positive MSM, respectively [12] . Focusing on anal cancer, incidence has been found to be higher among HIV-positive MSM compared to HIV-positive MSW (89.0 vs 34.7 per 100 000 person-years [7] ). Although data on anal cancer incidence by male sexual preference are not available at a population level, cancer registry-based studies have previously reported increased risk of anal cancer in never-married men [16] [17] [18] [19] , as a rough surrogate of MSM, in comparison to the general male population.
We expect the MSW included in this meta-analysis to be reasonably representative of the larger populations from which they were drawn. For HIV-negative MSW, studies with cytopathology results were more often in specific groups, for example patients with severe hemorrhoids [20] . However, these were only a minority of subjects, and no significant differences in prevalence were found versus the majority of HIV-negative MSW recruited from studies without cytopathology. Studies including HIV-positive MSW tended to recruit all patients screened in HIV clinics in a certain period of time, without other selection criteria apart from their HIV status, and there were no clear differences in anal HPV prevalence by studies with or without anal cytopathology. We also expect the large HIV-positive MSM sample included in the meta-analysis to be representative, given that HPV (16) infection is known to be ubiquitously elevated in this population, without any strong determinants [21, 22] . Nevertheless, HPV prevalence was slightly higher in studies including cytopathology, suggesting that these studies that tend to have a more clinical focus on screening might be over-representing HIV-positive MSM with existing anal HPV-related disease.
In HIV-negative MSM, in contrast, anal HPV prevalence was considerably higher in studies with concurrent cytopathology (ie, those with a more clinical focus), in comparison to those that only had HPV genotyping for research purposes, suggesting differing population selection. Two-thirds of included HIV-negative MSM did not have cytopathology diagnosis, of which the large majority were recruited with community-based sampling designs, or free walk-in sexually transmitted infection clinics [23] [24] [25] [26] [27] [28] [29] , whereas the subjects from studies with cytopathology (one-third of the included HIV-negative MSM population) tended to be recruited in HIV-prevention clinics specifically for men with an elevated risk of HIV infection [30] [31] [32] , or to have existing anal complaints [33] [34] [35] . Thus, although not all studies could be clearly categorized with respect to recruitment methods, there was a clear tendency of studies to over-represent HIV-negative MSM with sexual risk factors for anal HPV and related disease. This phenomenon explains the apparent discrepancy of anal HPV prevalence being similar in HIV-negative MSM and HIV-positive MSW in analyses irrespective of anal cytopathology, but higher in HIV-negative MSM when restricted to men with normal cytology only. We suggest that meta-analytical findings irrespective of anal cytopathological diagnosis are the most representative for comparing HPV prevalence between populations. In this respect, HIV-negative MSM are largely comparable to HIV-positive MSW.
The relative size of the populations of HIV-negative MSM and HIV-positive MSW is expected to vary substantially by setting. Whereas HIV-negative MSM are expected to be the more numerous of the 2 populations in high-income settings, HIV-positive MSW are proportionally much larger in settings of high HIV prevalence in sub-Saharan Africa. A major limitation of the studies included in this meta-analysis is the severe under-representation of data from Africa, where the main burden of male HIV infection is in MSW [36] . HPV16 prevalence in the few HIV-positive MSW from Africa (4%, n = 231) included in this meta-analysis was actually lower than that of HIV-positive MSW from Europe (17%, n = 214) or North America (18%, n = 97). Future studies assessing anal HPV prevalence in men by HIV and sexual preference are needed in African countries to address this knowledge gap.
With respect to primary prevention of anal cancer, some countries already recommend vaccination of MSM under the age of 45 years [37] or under the age of 27 years [38, 39] . However, this meta-analysis illustrates the high prevalence of HPV16 infection in these men, which, sends a warning about the potential efficacy of such an approach. Eventhough we were unable to stratify prevalence estimates by age groups, age has previously been found not to be associated with anal hrHPV infection among HIV-negative MSM [21, 22] , and increasing age was borderline significant negatively associated with anal hrHPV infection among HIV-positive MSM. Furthermore, a proportion of the HPV16-negative MSM in this meta-analysis are expected to have cleared a previous HPV16 infection (and would presumably do so again if reinfected), so that a large proportion of future anal cancers in the MSM included in this meta-analysis can be expected to arise among those with prevalent HPV16.
With respect to secondary prevention, HPV16 prevalence has been shown to be the best predictor of anal HSIL among HIVpositive MSM [40, 41] and of anal cancer [9] . This meta-analysis establishes that approximately one-third of HIV-positive MSM would test positive for anal HPV16 and require referral for detection and potentially treatment of anal HSIL, for example by high-resolution anoscopy, the current gold standard for anal HSIL detection. The proportions for HIV-positive MSW and HIV-negative MSM would be approximately equivalent at 10%.
Certain national guidelines for management of HIV-positive persons already make specific recommendations for secondary prevention of anal cancer [42] [43] [44] , whilst others do not [45] [46] [47] . For example, the European AIDS Clinical Society advises digital rectal exam (with or without anal cytology) for HIVpositive MSM every 1-3 years [42] . France also recommends anoscopy for HIV-positive MSM (or men with anal condyloma or a history of anal dysplasia), with the option of expanding this approach to all HIV-positive men in cases where the local infrastructure allows it [43] . New York State recommends digital rectal exam for all HIV-positive men, and annual cytology for HIV-positive MSM and men with anal condyloma [44] . Thus, where current recommendations exist, they rightly tend to focus on HIV-positive MSM.
CONCLUSION
Sexual preference and HIV infection are strong independent determinants of male anal HPV16 positivity, confirming HIVpositive MSM as a priority for anal cancer prevention. While much focus in studies on anal cancer prevention has also been on HIV-negative MSM, this group seems to be comparable in terms of anal HPV infection risk to HIV-positive MSW. In the absence of widespread routine data on anal cancer incidence in these populations, we propose that differences in anal HPV16 prevalence may be used as a surrogate for relative risks of anal cancer between these populations.
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